** Brokerage Mizuho raises healthcare conglomerate CVS Health's CVS.N PT to $70 from $58, with "outperform" rating
** New PT represents ~14% upside to the stock's close
** Brokerage says CVS is "an attractive investment opportunity given the diversification of its business"
** "We believe CVS' long-term adjusted EPS growth floor is predicated on market share gains and the success of the company's new cost-plus pharmacy reimbursement model" - brokerage adds
** Eighteen of 29 brokerages rate the stock "buy" or higher, eleven "hold"; their median PT is $70.89 - data compiled by LSEG
** CVS has fallen 12.4% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))